Medtronic Diabetes announces FDA clearance for MiniMed Go™ Smart MDI system featuring Instinct sensor made by Abbott

Rhea-AI Summary

Medtronic (NYSE: MDT) announced FDA 510(k) clearance of the MiniMed Go™ app and Smart MDI system on January 12, 2026. The system links the InPen smart insulin pen with Abbott's Instinct sensor to provide real-time glucose data, dose calculations, missed-dose alerts, and CareLink reporting. Cleared for insulin-requiring type 1 and type 2 diabetes ages 7+, and ages 2–6 under caregiver supervision. Commercial launch in the U.S. is expected in spring 2026. Compatibility of Simplera sensor remains under FDA review.

Positive

• FDA 510(k) clearance for MiniMed Go™ Smart MDI system
• System integrates InPen and Abbott Instinct sensor for real-time dosing and glucose data
• Cleared for ages 7+ and supervised use for ages 2–6
• Real-world data: Time in Range rose from 55.7% to 67.2% when users addressed >75% of Missed Dose alerts

Negative

• Compatibility of Simplera sensor with MiniMed Go™ is still under FDA review
• Commercial launch timing limited to an expected spring 2026 window (no definitive date)

News Market Reaction – MDT

-0.59%

1 alert

-0.59% News Effect

On the day this news was published, MDT declined 0.59%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

MDI population: more than 15 million people HbA1C impact: 0.4% Time in Range baseline: 55.7% +5 more

8 metrics

MDI population more than 15 million people Global diabetes patients relying on multiple daily injections

HbA1C impact 0.4% HbA1C increase from skipping two insulin doses per week

Time in Range baseline 55.7% TIR before consistently addressing missed dose alerts in prior Smart MDI data

Time in Range with alerts 67.2% TIR when >75% missed dose alerts addressed within one hour

Time in Range high-glucose 71.5% TIR when high glucose alerts addressed with bolus within one hour

Instinct wear duration 15 days Maximum wear time for Abbott Instinct continuous glucose sensor

Quarterly net sales $8,961 million Net sales for quarter ended Oct 24, 2025

Quarterly EPS $1.07 Diluted EPS for quarter ended Oct 24, 2025, up from $0.99

Market Reality Check

Price: $93.01 Vol: Volume 5,897,416 is sligh...

normal vol

$93.01 Last Close

Volume Volume 5,897,416 is slightly below 20-day average 6,135,404 ahead of this FDA news. normal

Technical Price 97.53 sits above the 200-day MA at 91.51, indicating a pre-news uptrend bias.

Peers on Argus

MDT was down 1.18% pre-release, while peers like BSX (-1.32%) and PHG (-1.2%) al...

MDT was down 1.18% pre-release, while peers like BSX (-1.32%) and PHG (-1.2%) also traded lower, but momentum scanners did not flag a broad sector move.

Historical Context

5 past events · Latest: Jan 07 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 07	Diabetes study data	Positive	-0.5%	Real-world MiniMed 780G data showing strong TIR even with missed boluses.
Jan 05	Conference appearance	Neutral	+3.0%	CEO and CFO scheduled to present and answer questions at JPM conference.
Dec 19	MiniMed IPO filing	Neutral	-0.9%	Filed Form S-1 for IPO of Diabetes business MiniMed on Nasdaq.
Dec 04	Dividend declaration	Positive	-0.6%	Announced <b>$0.71</b> Q3 FY26 cash dividend, continuing Dividend Aristocrat streak.
Dec 03	FDA clearance RAS	Positive	+0.0%	FDA cleared Hugo™ RAS for urologic procedures after Expand URO IDE success.

Pattern Detected

Recent positive operational and approval news has often seen mixed or negative next-day price reactions.

Recent Company History

Over the last few months, Medtronic has combined portfolio innovation with capital returns. On Dec 3, 2025, it received FDA clearance for the Hugo™ RAS system, followed by a $0.71 Q3 FY26 dividend declaration on Dec 4, 2025. An S-1 filing on Dec 19, 2025 outlined an IPO for the MiniMed diabetes unit. Early January 2026 brought MiniMed 780G real-world data and a planned J.P. Morgan conference appearance. Today’s MiniMed Go™ 510(k) clearance extends this diabetes-technology narrative.

Market Pulse Summary

This announcement highlights FDA 510(k) clearance for MiniMed Go™, integrating the InPen™ smart insu...

Analysis

This announcement highlights FDA 510(k) clearance for MiniMed Go™, integrating the InPen™ smart insulin pen with Abbott’s Instinct CGM for MDI users. It extends Medtronic’s diabetes technology push alongside earlier MiniMed 780G data and the planned MiniMed IPO. Investors may watch adoption among the >15 million MDI patients, real-world TIR outcomes versus prior Smart MDI data, and how this ecosystem positions MiniMed in advance of its planned public listing.

Key Terms

510(k), multiple daily injections, bolus

3 terms

510(k) regulatory

"today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its MiniMed Go™ app."

A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.

multiple daily injections medical

"insights for individuals on multiple daily injectionsGALWAY, Ireland, Jan. 12, 2026"

Multiple daily injections (MDI) is a diabetes treatment approach where a person takes several separate insulin shots each day—typically a long-acting dose to cover baseline needs and additional short-acting doses around meals. For investors, MDI signals demand for insulin supplies, injection devices and support services, and can affect adherence and health outcomes; think of it like needing both a monthly subscription and frequent one-off purchases, which shapes recurring revenue and product design opportunities.

bolus medical

"inject before eating (bolus) to keep blood sugar levels in check"

A bolus is a single, concentrated dose of a drug or fluid given all at once rather than slowly over time, like taking a quick gulp instead of sipping. Investors should care because a bolus can change how fast a medicine works, its side effect risks, and how regulators view dosing safety; those factors can materially affect clinical trial outcomes, approval chances and commercial prospects.

AI-generated analysis. Not financial advice.

MiniMed Go™ is the first and only smart MDI system that automatically integrates insulin dosing and glucose data in a single app to provide empowering insights for individuals on multiple daily injections

GALWAY, Ireland, Jan. 12, 2026 /PRNewswire/ -- Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its MiniMed Go™ app. The MiniMed Go™ Smart Multiple Daily Injection (MDI) system seamlessly integrates the InPen™ smart insulin pen with the Instinct sensor made by Abbott — all connected through the MiniMed Go™ app. This powerful combination delivers real-time, personalized insights and actionable guidance, including:

• Missed dose alerts to help minimize glucose highs
• A dose calculator that simplifies dose decision-making
• Action-oriented guidance if a user misses or miscalculates a dose
• CareLink™ software reporting for easier provider collaboration

The MiniMed Go™ system is cleared for individuals with insulin-requiring type 1 and type 2 diabetes aged 7 years and older, as well as for children ages 2 to 6 years under the supervision of an adult caregiver. Compatibility of the Simplera™ sensor with MiniMed Go™ is currently under FDA review.

Addressing a Significant Unmet Need 
There are more than 15 million people around the world with diabetes who rely on multiple daily injections. For these individuals, mealtimes can feel overwhelming and exhausting — and over time, this can lead to diabetes distress.^1,2 This involves determining the amount of carbs in their meal and calculating the right insulin dose to inject before eating (bolus) to keep blood sugar levels in check to avoid dangerous spikes or dips.

Missed boluses can significantly impact diabetes management and glycemic outcomes. Even skipping just two doses a week can raise HbA1C by as much as 0.4%, increasing the risk of both short- and long-term complications.³ Remembering when and how much insulin to dose isn't just a math problem — it's a daily burden that adds stress and fatigue, making diabetes management feel overwhelming.

Real-world data demonstrates that users of the previous generation Medtronic Smart MDI system saw meaningful improvements in glycemic control when consistently responding to actionable alerts. Specifically, the data showed that Time in Range (TIR) increased from 55.7% to 67.2% when users addressed more than 75% of Missed Dose alerts within an hour, and to 71.5% when users addressed Correct High Glucose alerts with a bolus within an hour. These results underscore the power of timely, actionable insights in helping users achieve better glycemic outcomes.⁴ The new MiniMed Go™ Smart MDI System delivers real-time, personalized insights and actionable guidance to optimize outcomes for users.

"For too long, people using injections have carried the weight of diabetes management without access to the algorithms that make automated insulin delivery systems so powerful," said Que Dallara, EVP and president of Medtronic Diabetes and CEO-designate of MiniMed. "MiniMed Go™ is designed to change that — bringing the smarts of an AID system to individuals who prefer an insulin pen. The system helps take the guesswork out of MDI therapy, delivering simplicity and confidence in every dose. We're pleased to expand our full-stack insulin delivery solutions, making it seamless for our customers to find a therapy that works for them — no matter where they are in their journey."

We expect the commercial launch of the MiniMed Go™ system to begin in the U.S. this spring.  Learn more here about MiniMed Go™.  

Frequently Asked Questions
Q: What is the MiniMed Go™ system?
A: The MiniMed Go™ system is a smart diabetes management solution that connects the InPen™ smart insulin pen and the Instinct sensor made by Abbott through the MiniMed Go™ app. It provides real-time glucose data, dose calculations, missed dose alerts, and actionable guidance, making MDI therapy easier and more connected.

Q: What is InPen™? 
A: The InPen™ is a reusable smart insulin pen that uses Bluetooth® technology to send dose information to a mobile app. Offering dose calculations and tracking, InPen™ helps take some of the mental math out of diabetes management.

Q: What is the Instinct sensor and how is it different?
A: Instinct, made by Abbott, offers up to 15 days of wear and a slim, discreet design. It's the world's smallest⁵ and thinnest⁶ integrated CGM.⁶

About the Diabetes Business at Medtronic
Medtronic Diabetes is on a mission to make diabetes more predictable with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront. 

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE: MDT), visit www.Medtronic.com and follow on LinkedIn. 

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

*Data was uploaded voluntarily from 22 October 2024 until 04 January 2025 in the CareLink™ Personal platform. Data aggregation and analysis was based on user consent and complied with local data privacy regulations.
⁺Sensor is water resistant up to 1 meter (3 feet) of water. Do not immerse longer than 30 minutes.
The sensor shape and appearance, Abbott, and Instinct are marks and/or designs of the Abbott group of companies in various territories and used under license.

1. Bergenstal RM, et al. Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes. Diabetes Care. 2021; Published online.
2. Monaghan M, Herbert LJ, Wang J, Holmes C, Cogen FR, Streisand R. Mealtime behavior and diabetes-specific parent functioning in young children with type 1 diabetes. Health Psychol. 2015 Aug;34(8):794-801. doi: 10.1037/hea0000204. Epub 2015 Feb 9. Published online.
3. Randlov, J, Poulsen, JU. How Much Do Forgotten Insulin Injections Matter to Hemoglobin A1c in People with Diabetes, J Diabetes Sci Technol. 2008; 2(2):229-235.
4. Laurenzi A, Edd SN, Adolfsson P, et al. Insights into the effective use of the Smart MDI system: Data from the first 1852 type 1 diabetes users. Diabet Med. 2025;42(12):e70161. doi:10.1111/dme.70161.
5. Among patient-applied sensors.
6. Data on file. Abbott Diabetes Care, Inc.

Contacts:
Janet Cho
Global Communications
+1 (818) 403-7028

Ryan Weispfenning
Investor Relations
+1 (763) 505-4626 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-diabetes-announces-fda-clearance-for-minimed-go-smart-mdi-system-featuring-instinct-sensor-made-by-abbott-302658516.html

SOURCE Medtronic plc

FAQ

What did Medtronic (MDT) announce on January 12, 2026 regarding MiniMed Go™?

Medtronic announced FDA 510(k) clearance of the MiniMed Go™ app and Smart MDI system integrating InPen and Abbott Instinct sensor.

When will Medtronic (MDT) commercially launch MiniMed Go™ in the U.S.?

Medtronic expects a U.S. commercial launch in spring 2026, with no exact date provided.

Which patients are eligible for the MiniMed Go™ Smart MDI system (MDT)?

The system is cleared for insulin-requiring type 1 and type 2 diabetes ages 7 and older, and ages 2–6 under adult caregiver supervision.

How does the MiniMed Go™ system improve glucose management for users?

The system delivers real-time glucose data, dose calculations, missed-dose alerts, and CareLink reporting to support timely, actionable dosing decisions.

Is Abbott's Simplera sensor compatible with MiniMed Go™ (MDT)?

Simplera compatibility is currently under FDA review and not yet cleared for use with MiniMed Go™.

What real-world performance data did Medtronic cite for the Smart MDI system?

Medtronic cited data showing Time in Range increased from 55.7% to 67.2% when users addressed over 75% of Missed Dose alerts within an hour.